Startups
Corbin Therapeutics, headquartered in Montreal, Quebec, was spun out of venture capital company AmorChem.
There are many unusual things about Shepherd Therapeutics, but one of them is its origin.
Based in Cambridge, MA and founded in February 2016, Relay Therapeutics focuses on developing therapeutics based on protein motion.
Jecure Therapeutics, based in San Diego, stated operations in mid-2016 with a focus on NASH and liver fibrosis.
Indalo Therapeutics is based in St. Louis and was formed in October 2016 from the merger of Antegrin Therapeutics and Cascadia Therapeutics.
Freenome, headquartered in South San Francisco, is focused on developing a diagnostic test for early detection of cancer and other diseases on the so-called “liquid biopsy,” in other words, blood.
Fortis Therapeutics is focused on immuno-oncology, specifically on developing an ADC for multiple myeloma and late-stage prostate cancer, including both the adenocarcinoma and neuroendocrine types.
Based in Toronto, Ontario, Fibrocor Therapeutics was launched in January 2017.
DMD Therapeutics is based in Seattle, although at present it is a virtual company, and, as its name suggests, is focused on developing therapeutics for DMD.
The Series A was led by GV, with participation from AtlasVenture, Takeda Ventures, Vertex Ventures HC, Amgen Ventures, Alexandria Venture Investments, and ShangPharma Group.
PRESS RELEASES